FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2178727026> ?p ?o ?g. }

• W2178727026 endingPage "485" @default.
• W2178727026 startingPage "477" @default.
• W2178727026 abstract "Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy with high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two patients who received all components of the therapy are evaluable for response, and all patients are evaluable for toxicity. Sites of disease included lung, liver, subcutaneous nodules, and intra-abdominal metastases. One complete response (CR) and five partial responses (PRs) resulted from treatment (19% response rate). The median response duration was 5 months, with the durable CR continuing at 31+ months and one durable PR continuing for 13 months. Sites of response included lung, liver, subcutaneous nodules, and lymph nodes. Response, response duration, or site of response did not correlate with the total dose of IL-2 administered, rebound lymphocytosis, or the number of LAK cells infused. Toxicity included hypotension, fluid retention with a capillary leak syndrome in most patients, and transient multiorgan dysfunction that resolved promptly after the completion of therapy. Adverse cardiac events occurred in 16% of patients, with one myocardial infarction leading to a death. This study confirms the activity of the initial IL-2/LAK cell regimen in metastatic melanoma reported by Rosenberg et al, supporting the concept of adoptive immunotherapy as an important new treatment approach for this disease." @default.
• W2178727026 created "2016-06-24" @default.
• W2178727026 creator A5009574158 @default.
• W2178727026 creator A5025813401 @default.
• W2178727026 creator A5033346506 @default.
• W2178727026 creator A5044470461 @default.
• W2178727026 creator A5047073824 @default.
• W2178727026 creator A5063294358 @default.
• W2178727026 creator A5065466887 @default.
• W2178727026 creator A5068688822 @default.
• W2178727026 creator A5084347950 @default.
• W2178727026 creator A5090477488 @default.
• W2178727026 date "1989-04-01" @default.
• W2178727026 modified "2023-10-18" @default.
• W2178727026 title "A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma." @default.
• W2178727026 cites W1500666301 @default.
• W2178727026 cites W1529386421 @default.
• W2178727026 cites W155421318 @default.
• W2178727026 cites W1568103831 @default.
• W2178727026 cites W1576953154 @default.
• W2178727026 cites W1643040145 @default.
• W2178727026 cites W1904436785 @default.
• W2178727026 cites W1950009610 @default.
• W2178727026 cites W1985981664 @default.
• W2178727026 cites W2012913493 @default.
• W2178727026 cites W2021847833 @default.
• W2178727026 cites W2088029302 @default.
• W2178727026 cites W2149724818 @default.
• W2178727026 cites W2322553446 @default.
• W2178727026 cites W2326245275 @default.
• W2178727026 cites W2331908659 @default.
• W2178727026 cites W2336865510 @default.
• W2178727026 cites W2403920738 @default.
• W2178727026 cites W2409244694 @default.
• W2178727026 cites W2413986234 @default.
• W2178727026 cites W3135115018 @default.
• W2178727026 cites W3111683085 @default.
• W2178727026 doi "https://doi.org/10.1200/jco.1989.7.4.477" @default.
• W2178727026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2647913" @default.
• W2178727026 hasPublicationYear "1989" @default.
• W2178727026 type Work @default.
• W2178727026 sameAs 2178727026 @default.
• W2178727026 citedByCount "232" @default.
• W2178727026 countsByYear W21787270262012 @default.
• W2178727026 countsByYear W21787270262013 @default.
• W2178727026 countsByYear W21787270262014 @default.
• W2178727026 countsByYear W21787270262015 @default.
• W2178727026 countsByYear W21787270262016 @default.
• W2178727026 countsByYear W21787270262017 @default.
• W2178727026 countsByYear W21787270262018 @default.
• W2178727026 countsByYear W21787270262019 @default.
• W2178727026 countsByYear W21787270262020 @default.
• W2178727026 countsByYear W21787270262021 @default.
• W2178727026 countsByYear W21787270262022 @default.
• W2178727026 countsByYear W21787270262023 @default.
• W2178727026 crossrefType "journal-article" @default.
• W2178727026 hasAuthorship W2178727026A5009574158 @default.
• W2178727026 hasAuthorship W2178727026A5025813401 @default.
• W2178727026 hasAuthorship W2178727026A5033346506 @default.
• W2178727026 hasAuthorship W2178727026A5044470461 @default.
• W2178727026 hasAuthorship W2178727026A5047073824 @default.
• W2178727026 hasAuthorship W2178727026A5063294358 @default.
• W2178727026 hasAuthorship W2178727026A5065466887 @default.
• W2178727026 hasAuthorship W2178727026A5068688822 @default.
• W2178727026 hasAuthorship W2178727026A5084347950 @default.
• W2178727026 hasAuthorship W2178727026A5090477488 @default.
• W2178727026 hasConcept C126322002 @default.
• W2178727026 hasConcept C141071460 @default.
• W2178727026 hasConcept C143998085 @default.
• W2178727026 hasConcept C2776694085 @default.
• W2178727026 hasConcept C2777371288 @default.
• W2178727026 hasConcept C2777658100 @default.
• W2178727026 hasConcept C2778690821 @default.
• W2178727026 hasConcept C2778822529 @default.
• W2178727026 hasConcept C2780126324 @default.
• W2178727026 hasConcept C2781413609 @default.
• W2178727026 hasConcept C2908885563 @default.
• W2178727026 hasConcept C502942594 @default.
• W2178727026 hasConcept C71924100 @default.
• W2178727026 hasConcept C90924648 @default.
• W2178727026 hasConceptScore W2178727026C126322002 @default.
• W2178727026 hasConceptScore W2178727026C141071460 @default.
• W2178727026 hasConceptScore W2178727026C143998085 @default.
• W2178727026 hasConceptScore W2178727026C2776694085 @default.
• W2178727026 hasConceptScore W2178727026C2777371288 @default.
• W2178727026 hasConceptScore W2178727026C2777658100 @default.
• W2178727026 hasConceptScore W2178727026C2778690821 @default.
• W2178727026 hasConceptScore W2178727026C2778822529 @default.
• W2178727026 hasConceptScore W2178727026C2780126324 @default.
• W2178727026 hasConceptScore W2178727026C2781413609 @default.
• W2178727026 hasConceptScore W2178727026C2908885563 @default.
• W2178727026 hasConceptScore W2178727026C502942594 @default.
• W2178727026 hasConceptScore W2178727026C71924100 @default.
• W2178727026 hasConceptScore W2178727026C90924648 @default.
• W2178727026 hasIssue "4" @default.
• W2178727026 hasLocation W21787270261 @default.
• W2178727026 hasLocation W21787270262 @default.
• W2178727026 hasOpenAccess W2178727026 @default.

• next